Your institution may have access to this item. Find your institution then sign in to continue.
Title
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study.